Telmisartan protects against insulin resistance by attenuating inflammatory response in rats

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 31, Issue 3, 2011, Pages 317-323

  Xu, Xizhen ^a   Yin, Xiaoming ^a   Feng, Wenjing ^a   Li, Geng ^a   Wang, Daowen ^a   Tu, Ling ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Inflammation; Insulin resistance; Obesity; Telmisartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; C REACTIVE PROTEIN; CCL2 PROTEIN, RAT; CYTOKINE; I KAPPA B; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; TELMISARTAN;

ANIMAL; ARTICLE; BLOOD; FAT INTAKE; GENETICS; INFLAMMATION; INSULIN RESISTANCE; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CYTOKINES; DIETARY FATS; I-KAPPA B PROTEINS; INFLAMMATION; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER;

EID: 80455123687     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-011-0374-7     Document Type: Article

References (38)

1. Kurtz TW. Beyond the classic angiotensin-receptorblocker profile. Nat Clin Pract Cardiovasc Med, 2008,5 (Suppl 1):S19-26
2. Andraws R, Brown DL. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol, 2007, 99(7):1006-1012 (Pubitemid 46483294)
3. McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med, 2010,362(16):1477-1490
4. Sugimoto K, Qi NR, Kazdová L, et al. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension, 2006,47(5):1003-1009 (Pubitemid 44297575)
5. He H, Yang D, Ma L, et al. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator- activated receptor-delta- dependent pathways. Hypertension, 2010,55(4):869-879
6. Rong X, Li Y, Ebihara K, et al. Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia, 2010 [PMID: 20390403]
7. Zanchi A, Dulloo AG, Perregaux C, et al. Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties. Am J Physiol Endocrinol Metab, 2007,293(1):E91-E95 (Pubitemid 47105921)
8. Shimabukuro M, Tanaka H, Shimabukuro T. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens, 2007,25(4):841-848 (Pubitemid 46398879)
9. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest, 2006,29(11):957-961 (Pubitemid 46344228)
10. Enjoji M, Kotoh K, Kato M, et al. Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. Int J Mol Med, 2008,22(4):521-527
11. Liang H, Yin B, Zhang H, et al. Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF-alpha signaling protected Wistar rats from diet-induced obesity and insulin resistance. Endocrinology, 2008,149(6): 2943-2951 (Pubitemid 351724499)
12. Xu X, Zhao CX, Wang L, et al. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes, 2010,59(4):997-1005
13. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension, 2004,43(5):993-1002 (Pubitemid 38579904)
14. Zhao C, Wang P, Xiao X, et al. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension, 2003,42(5):1026-1033 (Pubitemid 37413748)
15. Tu L, Xu X, Wan H, et al. Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum Gene Ther, 2008,19(4):318-330 (Pubitemid 351591428)
16. Tam CS, Viardot A, Clément K, et al. Short-term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans. Diabetes, 2010,59(9):2164-2170
17. Haus JM, Solomon TP, Marchetti CM, et al. Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance. J Clin Endocrinol Metab, 2010,95(1):323-327
18. Tzotzas T, Papadopoulou FG, Tziomalos K, et al. Rising serum 25-hydroxy-vitamin D levels after weight loss in obese women correlate with improvement in insulin resistance. J Clin Endocrinol Metab, 2010,95(9):4251-4257
19. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol, 2010,72:219-246
20. Xu JW, Morita I, Ikeda K, et al. C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol, 2007,21(2):564-573 (Pubitemid 46184902)
21. Solomon SS, Odunusi O, Carrigan D, et al. TNF-alpha inhibits insulin action in liver and adipose tissue: A model of metabolic syndrome. Horm Metab Res, 2010,42(2): 115-121
22. Jager J, Gremeaux T, Cormont M, et al. Interleukin- 1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology, 2007,148(1):241-251 (Pubitemid 46021456)
23. Osborn O, Brownell SE, Sanchez-Alavez M, et al. treatment with an interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine, 2008,44(1):141-148
24. Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci USA, 2009,106(33):13 998-14 003
25. Owyang AM, Maedler K, Gross L, et al. XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. Endocrinology, 2010,151(6):2515-2527
26. Cintra DE, Pauli JR, Araújo EP, et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol, 2008,48(4):628-637
27. Hong EG, Ko HJ, Cho YR, et al. Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes, 2009,58(11):2525-2535
28. Fernandez-Veledo S, Vila-Bedmar R, Nieto-Vazquez I, et al. c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-alpha induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists. J Clin Endocrinol Metab, 2009,94(9):3583-3593
29. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes, 2006,55(8):2392-2397 (Pubitemid 44743640)
30. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein in obesity and insulin resistance. Proc Natl Acad Sci U S A, 2003,100(12):7265-7270 (Pubitemid 36706427)
31. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest, 2006,116(6):1494-1505
32. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997,336(15):1066-1071 (Pubitemid 27163860)
33. Itani SI, Ruderman NB, Schmieder F, et al. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB- alpha. Diabetes, 2002,51(7):2005-2011 (Pubitemid 34729001)
34. Goyal S, Arora S, Bhatt TK, et al. Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes. Chem Biol Interact, 2010,185(3):271-280
35. Iwanami J, Mogi M, Tsukuda K, et al. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. J Hypertens, 2010,28(8):1730-1737
36. Clemenz M, Frost N, Schupp M, et al. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes, 2008,57(5):1405-1413
37. Feng X, Luo Z, Ma L, et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR delta/ AMPK pathway. J Cell Mol Med, 2010 [PMID: 20477906]
38. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation, 2004,110(11):1507-1512 (Pubitemid 39238031)